Dr. John Cush RheumNow
4 years 4 months ago
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis
This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery.
https://t.co/65llG1nULF https://t.co/YQAJ9tIluF
Dr. John Cush RheumNow
4 years 4 months ago
New download available!
Smart rules for patients—a patient handout.
https://t.co/8yjCwb95c5 https://t.co/baFOavYO99
Dr. John Cush RheumNow
4 years 4 months ago
Diagnostic Delays in Spondyloarthritis Still Prolonged
Previously quoted average delay in diagnosing axSpA may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between 5 and 6 years.
https://t.co/6T9pck7nLa https://t.co/nwGBef2Gja
Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.
This webinar presented exerpts from these lectures along with audience Q & A
Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD
Drug Targeting in PsA Bruce Kirkham, MD
PsA Registries and Real World Data Alexis Ogdie, MD
This session was sponsored by Abbvie
Eric Topol EricTopol
4 years 4 months ago
Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9
Dr. John Cush RheumNow
4 years 4 months ago
Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/VvKZaeVumy https://t.co/1shpS0Ajn4
Dr. John Cush RheumNow
4 years 4 months ago
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign?
https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA
Dr. John Cush RheumNow
4 years 4 months ago
NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/W6kjahdLEu https://t.co/QyTmlhb235
The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive.
Dr. John Cush RheumNow
4 years 4 months ago
Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain
An interesting read from @CreakyJoints. Check it out our synopsis.
https://t.co/dHlUrWcyjB https://t.co/pL5Sn5eD7h
Dr. John Cush RheumNow
4 years 4 months ago
Comparison of NHANES survey data from 2 eras (2007–2008 and 2017–2018) shows that prevalence blood pressure control decreased from 65% to 55% over 10 yrs(P=0.03); while lipid control remained stable; and diabetes med use rose 71% to 95% https://t.co/WIWBCYo2Yi https://t.co/mS7uVIiyUq
Peter Nash drpnash
4 years 4 months ago
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!
Dr. John Cush RheumNow
4 years 4 months ago
Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/5tomZsaaU6 https://t.co/yAMGY5nlCU
